Today, we’re going on a journey to explore the estimated Strides Pharma Share Price Target for the years 2023 to 2050. We will use our Research and the company’s growth prospects to make a prediction. By the end of our journey, you will have a better understanding of the expected Strides Pharma Share Price Target.
Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bangalore, India. The company operates in two business verticals: Regulated Markets and Emerging Markets.
Strides boasts a global manufacturing footprint with eight manufacturing facilities distributed across four continents. Of these, five are US FDA-approved, while the remaining two cater to other world markets.
The company also has a dedicated R&D facility in India, equipped with global filing capabilities, and has a significant presence in over 100 countries.”
Overview of Strides Pharma
| Name | Strides Pharma Science Limited |
|---|---|
| Symbol | STRIDES |
| Industry | Pharmaceuticals |
| Founded | 1990 |
| CEO | R. Ananthanarayanan |
| Headquarters | Bangalore, India |
| Exchange | NSE, BSE |
| Country | India |
| Locations | India, Singapore, Australia, Europe, Africa, North America |
| Website | strides.com |
| Profile | Strides Pharma Science |
Strides Pharma Science Limited is a leading global pharmaceutical company headquartered in Bangalore, India. The company was founded in 1990 and is listed on the National Stock Exchange of India and the Bombay Stock Exchange.
Strides Pharma is engaged in the development and manufacture of a wide range of pharmaceutical products, including branded and generic drugs, biosimilars, and specialty products.
Strides Pharma has a diverse portfolio of products across therapeutic areas such as anti-infectives, cardiovascular, central nervous system, and oncology. The company has a strong focus on innovation and R&D and has a pipeline of several new products in development. Strides Pharma has a global workforce of over 6,000 employees and operates in multiple locations across the world.
We will analyze the performance of the company’s shares in recent times and provide you with a well-researched Strides Pharma Share price target for 2023, 2025, 2030 to 2050.
Keep an eye on Strides Pharma’s share price today with real-time updates, and examine its performance on the stock market through comprehensive charts that display the fluctuations in Strides Pharma’s stock price. we will also take into analyst recommendations from various brokerage firms at the end of the article.
Above, the chart presents historical prices for Strides Pharma stock, illustrating its trending behavior. Below, the table provides detailed data on the stock’s open, high, low, and close prices, offering a comprehensive perspective for stock analysis.
Brokerage Firms
An effective method for evaluating the Strides Pharma share price Target is by examining research reports and analyses conducted by reputable financial institutions and brokerage firms. Please find the latest research reports available on Strides Pharma.
| DATE | AUTHOR | TARGET | TYPE |
|---|---|---|---|
| 31 OCT 2023 | ICICI Securities Limited | 495.00 |
Hold
|
| 26 SEP 2023 | ICICI Securities Limited | 495.00 |
Sell
|
| 03 AUG 2023 | ICICI Securities Limited | 460.00 |
Hold
|
| 01 JUN 2023 | Sharekhan | 450.00 |
Buy
|
| 28 FEB 2023 | Geojit BNP Paribas | 363.00 |
Buy
|
| 25 JAN 2023 | ICICI Securities Limited | 462.00 |
Buy
|
Fundamentals of Strides Pharma
The fundamental analysis of Strides Pharma Limited focuses on key factors to better understand the company’s valuation.
We will analyze the performance of the company’s shares in recent times and provide you with a well-researched Strides Pharma price target for 2023, 2025 to 2030, based on our Research knowledge and forecasting.
Based on our research and analysis, we believe that the minimum share price target for Strides Pharma in 2023 is Rs.550, while the maximum target is Rs.650. The reason behind this forecast is the company’s strong financial performance in the first three-quarters of FY23, which has been driven by robust growth in the US and Other Regulated Markets.
The company has also made significant progress in its R&D pipeline, with several new product launches expected in the coming quarters. Additionally, the company’s focus on cost optimization and operational efficiency is expected to drive margin expansion in the near term.
Looking ahead to 2024, we expect the minimum share price target for Strides Pharma to be Rs.700, while the maximum target is Rs.800. The reason behind this forecast is the company’s continued growth momentum in the US and Europe, driven by new product launches and customer acquisitions.
The company’s focus on R&D and innovation is also expected to yield positive results, with several new product filings and approvals expected in the coming years. Additionally, the company’s strong balance sheet and cash flow generation are expected to support future growth initiatives and shareholder returns.
For 2025, we expect the minimum share price target for Strides Pharma to be Rs.900, while the maximum target is Rs.1000. The reason behind this forecast is the company’s expected entry into new geographies and therapeutic areas, which is expected to drive revenue growth and market share gains.
The company’s focus on digital transformation and automation is also expected to drive operational efficiency and cost savings, which will support margin expansion and profitability. Additionally, the company’s strong track record of M&A and strategic partnerships is expected to create value for shareholders in the long term.
For 2027, we expect the minimum share price target for Strides Pharma to be Rs.1400, while the maximum target is Rs.1500. The reason behind this forecast is the company’s expected growth in the emerging markets, which are high-growth areas with significant revenue potential.
The company’s focus on expanding its presence in these markets through strategic partnerships and acquisitions is expected to drive revenue growth and market share gains. Additionally, the company’s strong track record of M&A and strategic partnerships is expected to create value for shareholders in the long term.
Looking ahead to 2030, we expect the minimum share price target for Strides Pharma to be Rs.2000, while the maximum target is Rs.2500. The reason behind this forecast is the company’s expected growth in the biosimilars and specialty segments, which are high-growth areas with significant revenue potential.
The company’s focus on innovation and R&D is expected to yield positive results in these areas, with several new product launches and approvals expected in the coming years. Additionally, the company’s strong balance sheet and cash flow generation are expected to support future growth initiatives and shareholder returns.
For 2035, we expect the minimum share price target for Strides Pharma to be Rs.3000, while the maximum target is Rs.3500. The reason behind this forecast is the company’s expected growth in the US and Europe, driven by new product launches and customer acquisitions.
The company’s focus on R&D and innovation is also expected to yield positive results, with several new product filings and approvals expected in the coming years. Additionally, the company’s strong track record of M&A and strategic partnerships is expected to create value for shareholders in the long term.
Looking ahead to 2040, we expect the minimum target for Strides Pharma to be Rs.5000, while the maximum target is Rs.6000. The reason behind this forecast is the company’s expected growth in the biosimilars and specialty segments, which are high-growth areas with significant revenue potential.
The company’s focus on innovation and R&D is expected to yield positive results in these areas, with several new product launches and approvals expected in the coming years. Additionally, the company’s strong balance sheet and cash flow generation are expected to support future growth initiatives and shareholder returns.
Looking ahead to 2050, we expect the minimum target for Strides Pharma to be Rs.8000, while the maximum target is Rs.10000. The reason behind this forecast is the company’s expected growth in the emerging markets, which are high-growth areas with significant revenue potential.
The company’s focus on expanding its presence in these markets through strategic partnerships and acquisitions is expected to drive revenue growth and market share gains. Additionally, the company’s strong track record of M&A and strategic partnerships is expected to create value for shareholders in the long term.
Competitors of Strides Pharma
| Name | Market Cap. (Rs. cr.) | Total Assets |
| Sun Pharma | 260,807.71 | 31,341.03 |
| Cipla | 97,068.77 | 24,638.09 |
| Divis Labs | 89,768.20 | 12,705.42 |
| Dr Reddys Labs | 89,681.84 | 20,474.80 |
| Mankind Pharma | 68,220.21 | 7,783.91 |
| Torrent Pharma | 65,374.12 | 11,021.52 |
| Zydus Life | 57,979.05 | 18,461.90 |
Analyst Recommendations
Strides Pharma Buy or Sell
Daily Low / High
How to Buy Strides Pharma Stock
- Click on the “Open an Account“
- Fill in the required details
- Complete the verifying your identity
- Login to Your Account
- Search for Strides Pharma
- Place an Order.
| Telegram Channel | 👉 Click Here |
| WhatsApp Channel | 👉 Click Here |
| Year | Minimum Target | Maximum Target |
|---|---|---|
| 2023 | Rs. 550 | Rs. 650 |
| 2024 | Rs. 700 | Rs. 800 |
| 2025 | Rs. 900 | Rs. 1000 |
| 2026 | Rs. 1100 | Rs. 1200 |
| 2027 | Rs. 1400 | Rs. 1500 |
| 2030 | Rs. 2000 | Rs. 2500 |
| 2035 | Rs. 3000 | Rs. 3500 |
| 2040 | Rs. 5000 | Rs. 6000 |
| 2050 | Rs. 8000 | Rs. 10000 |
– According to Google historical data, the price of Strides Pharma on 22 Aug 2003 was ₹97.65.
– As of 1 November 2023, the current share price of Strides Pharma is ₹480.60 Check out today’s current share price.
– Based on our analysis, the maximum share price target for Strides Pharma in 2023 could be ₹ 650.
To stay updated with the latest information related to the stock market and receive live stock market updates, follow Sharedhan and stay connected with us. Check out Today’s Share Market Open or Closed India.
I would like to remind you that I am not authorized by SEBI to provide any financial advice or recommendations. As you know, Share price prediction is not an exact science, That’s why I am conducting in-depth research and using different AI tools to predict share prices. My purpose is only educational, and I am using AI to see what the future of the stock might look like.
Disclaimer– These Share Price Targets for “Strides Pharma Share Price Target” are only provided for informational purposes only. It does not constitute a recommendation to buy, sell, or hold Strides Pharma stock. Investors should conduct their own research and analysis and consult with financial experts before making any investment decisions— Sharedhan.com
